Article: Neurocrine Biosciences Completes Enrollment in Chronic and Transient Phase II Insomnia Clinical Trials.

Neurocrine Expected to Initiate Phase III Pivotal Clinical Trials

SAN DIEGO, May 10 /PRNewswire/ --

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the Company has completed enrollment in its Phase II transient and chronic insomnia clinical trials with NBI-34060 and is expected to report results at the end of June 2001. In addition, the company reported the initiation of multiple dose ranging and efficacy based clinical trials for its immediate and modified release formulations, the results of which will be released during the year. Based on the results of these studies, the company is expecting to move into multiple Phase III clinical ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!